ACHONDROPLASIA
Clinical trials for ACHONDROPLASIA explained in plain language.
Never miss a new study
Get alerted when new ACHONDROPLASIA trials appear
Sign up with your email to follow new studies for ACHONDROPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with dwarfism: daily shot may boost growth
Disease control OngoingThis study tests a daily injection called BMN 111 in about 70 children with achondroplasia, the most common form of dwarfism. The goal is to see if the drug is safe and helps children grow taller over several years. All participants had already received BMN 111 or a placebo in a …
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could a daily injection spare babies with dwarfism from risky neck surgery?
Disease control OngoingThis study tests a drug called vosoritide in infants with achondroplasia (the most common form of dwarfism) who are at high risk of needing a surgery to relieve pressure on the spinal cord at the base of the skull. The main goal is to see if the drug is safe and if it can help en…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Growth drug shows promise for kids with dwarfism
Disease control OngoingThis study tests a drug called BMN 111 in children with achondroplasia, the most common form of dwarfism. The goal is to see if it safely helps them grow taller over several years. About 119 children who completed an earlier study will take the drug and be monitored for growth, d…
Matched conditions: ACHONDROPLASIA
Phase: PHASE3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Hope for growth: new drug shows promise in Long-Term achondroplasia study
Disease control OngoingThis study looks at the long-term safety and effects of a daily injection called BMN 111 in children with achondroplasia, a common form of dwarfism. It includes 30 children who have already taken the drug for two years in a previous study. The goal is to see if the drug remains s…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo aims to boost growth in kids with dwarfism
Disease control OngoingThis study tests whether giving two weekly injections together can improve growth in children aged 2 to 11 with achondroplasia, a common cause of dwarfism. The drugs, navepegritide and lonapegsomatropin, are designed to increase height. The trial will measure growth rate and moni…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New oral drug shows promise for helping children with dwarfism grow
Disease control ENROLLING_BY_INVITATIONThis study tests a daily oral drug called infigratinib in 300 children with achondroplasia, the most common form of dwarfism. The drug aims to improve bone growth by targeting a specific protein. Researchers will monitor safety and growth over several years, including children wh…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Weekly shot shows promise for helping kids with dwarfism grow
Disease control ENROLLING_BY_INVITATIONThis study tests a weekly injection called TransCon CNP in children and teens with achondroplasia, the most common form of dwarfism. The goal is to see if it is safe and helps improve growth over several years. Participants who completed a previous TransCon CNP trial can join thi…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2, PHASE3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC